Human/mouse chimeric antibodies and their interaction with human anti-murine antibodies
Author Information
Author(s): M. Hosonol, K. Endo, H. Sakahara, Y. Watanabe, T. Saga, T. Nakai, C. Kawai, A. Matsumori, T. Yamada, T. Watanabe, J. Konishi
Primary Institution: Kyoto University Hospital
Hypothesis
The study investigates the properties of human anti-murine antibodies (HAMA) in patients receiving murine monoclonal antibodies and the potential of human/mouse chimeric antibodies to reduce HAMA response.
Conclusion
Human/mouse chimeric antibodies show promise in reducing the immune response in patients who develop HAMA after receiving murine monoclonal antibodies.
Supporting Evidence
- All seven patients developed HAMA after receiving murine monoclonal antibodies.
- Human/mouse chimeric antibodies showed minimal reactivity with HAMA positive sera.
- Five out of seven patients were reactive with murine MoAb Fab.
- HAMA was composed of antibodies responsive to the CH1 or CL region of murine IgG.
- Significant correlation was observed between HAMA titers determined by ELISA and HPLC.
Takeaway
Some patients develop antibodies against mouse antibodies, which can make treatments less effective, but new chimeric antibodies made from both human and mouse parts might help.
Methodology
The study used size exclusion high performance liquid chromatography (HPLC) and enzyme linked immunosorbent assay (ELISA) to analyze HAMA in patient sera.
Limitations
The study is limited by the small sample size and the variability in HAMA response among patients.
Participant Demographics
Seven patients with colorectal cancer, pancreatic cancer, malignant melanoma, or myocardial infarction who had previously received murine monoclonal antibodies.
Want to read the original?
Access the complete publication on the publisher's website